Dataset Information


Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

ABSTRACT: BACKGROUND:The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib, in combination with endocrine therapy (ET), significantly prolonged progression-free survival in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) in PALOMA-2 and PALOMA-3. Neutropenia and palbociclib dose reductions/interruptions occurred more frequently in the Japanese versus overall populations. We evaluated neutropenia patterns, palbociclib dose management, and clinical responses after dose reduction in Japanese patients in PALOMA-2 and PALOMA-3 and a single-arm Japanese phase 2 study. METHODS:PALOMA-2 and the Japanese phase 2 study enrolled postmenopausal women with estrogen receptor-positive, HER2- ABC who had not received prior systemic therapy for advanced disease; PALOMA-3 enrolled women with HR+/HER2- ABC, regardless of menopausal status, whose disease had progressed after prior ET. Palbociclib (125 mg/day) was administered 3 weeks on/1 week off. Dose reduction/interruption, cycle delay, tumor response, and laboratory-assessed neutropenia were analyzed in Japanese patients who received palbociclib. RESULTS:A total of 101 Japanese patients received palbociclib?+?ET. Among Japanese patients in the 3 studies, the frequency of all-grade/grade 3/grade 4 neutropenia was 94%/53%/34%, 100%/69%/21%, and 100%/67%/26%, respectively. Twenty (63%), 28 (67%), and 15 (56%) patients required palbociclib dose reduction. Dose interruption or reduction did not affect palbociclib treatment duration, and durable tumor response was observed despite dose reduction. CONCLUSION:Neutropenia was manageable with dose modifications, without affecting palbociclib treatment duration or efficacy. TRIAL REGISTRATION:Pfizer (NCT01740427, NCT01684215, NCT01942135).

PROVIDER: S-EPMC6694088 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6975938 | BioStudies
| S-EPMC6399183 | BioStudies
| S-EPMC6122240 | BioStudies
| S-EPMC7068918 | BioStudies
| S-EPMC8100571 | BioStudies
| S-EPMC7920865 | BioStudies
| S-EPMC5888946 | BioStudies
| S-EPMC6330732 | BioStudies
| S-EPMC7568717 | BioStudies
| S-EPMC5061543 | BioStudies